DARE BIOSCIENCE INC (DARE)
US23666P1012 - Common Stock
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases ...
Top movers in Wednesday's session
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Which stocks are experiencing notable movement on Wednesday?
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women Pivotal Phase 3 contraceptive efficacy clinical study of...
DARE Stock Earnings: Dare Bioscience Beats EPS, Beats Revenue for Q4 2023
DARE stock results show that Dare Bioscience beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
DARE Stock Earnings: Dare Bioscience Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dare Bioscience (NASDAQ:DARE) just reported results for the fourth quarter of 2...
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
Conference Call and Webcast Today at 4:30 p.m. ET...
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to get into the biggest pre-market stock movers as we check out all of the hottest news happening on Thursday morning!
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
There are no FDA-approved treatments for female sexual arousal disorder...
Daré Bioscience announces executive team changes (NASDAQ:DARE)
DARE Bioscience announces retirement of CFO Lisa Walters-Hoffert and resignation of CCO John Fair.
Daré Bioscience to eliminate CFO and CCO roles to rein in costs (NASDAQ:DARE)
Daré Bioscience (DARE) said on Friday that co-founder and chief financial information Lisa Walters-Hoffert will retire, effective January 26. The company said
Daré Bioscience Announces Executive Team and Board of Directors Changes
SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced changes in...
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
Grant funds support activities that will aid the ultimate development of bacteria-based biotherapeutic products designed to benefit women and newborns...
Organon says Xaciato now available nationwide (NYSE:OGN)
Organon (OGN) said that Xaciato, a formulation of clindamycin phosphate, is now available nationwide for the treatment of bacterial vaginosis in females aged 12
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and Other...
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
$5 million at closing and up to $7 million of additional committed funding...
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
Data Support Continued Clinical Development of DARE-PDM1 and its Potential as a First-in-Category Treatment for Primary Dysmenorrhea...
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study
DARE-PTB1 is being developed as a treatment to reduce the risk of preterm birth, for which there are no FDA-approved treatment options Up to approximately...
Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause
DARE-VVA1 has the potential to be the first therapeutic non-hormonal vaginal option for the treatment of moderate to severe dyspareunia, a symptom of...
Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update
Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™: receipt of $1.8 million triggered by achievement of...
Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program
Additional Analyses of Phase 2b Data Conducted in Population of Study Participants with Female Sexual Interest/Arousal Disorder (FSIAD), With Primary...
Daré stock rises on $1.8M milestone from Organon for Xaciato
Daré Bioscience stock rose after securing $1.8M milestone payment from Organon related vaginal gel Xaciato. Read more here
Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has...
Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update
Conference Call and Webcast Today at 4:30 p.m. ET Second Half 2023 Anticipated Milestones (target indication(s)): XACIATO™ First Commercial SaleOvaprene®...
Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings
DARE-HRT1 Demonstrated Preliminary Treatment Efficacy for Both Vasomotor Symptoms (VMS) and Genitourinary Syndrome of Menopause (GSM) The North...
Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will...